title: Our experience with antidepressant treatment in the obese and type 2 diabetics.
abstract: We established depressive symptoms prevalence in 100 patients recommended to our obesity clinic and we started antidepressant treatment in 41 of them. It has been noted that administration of SSRI leads to weight reduction after 6 months, but is followed by a weight increase later. Our experience shows that 12 months long administration of bupropion and tianeptine leads to continuous weight loss. Antidepressant administration leads to an increase in pharmacotherapy adherence, which is significantly higher than in diet and psychotherapy alone. In diabetics, antidepressants reduce glucose levels, too. Their influence on weight and diabetes compensation is, however, smaller than in "classic" anti-obesity drugs, sibutramine and orlistat.
authors.affiliation: Third Medical Department, First Faculty of Medicine, Charles University, Prague, Czech Republic. stepan.svacina@lf1.cuni.cz
authors.forename: S
authors.initials: S
authors.lastname: Svacina
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D000928:Antidepressive Agents; D001786:Blood Glucose; D017367:Selective Serotonin Reuptake Inhibitors